ArticleInternational journal of pharmaceutics: X2026
Fabrication and efficacy evaluation of scopolamine-loaded dissolving microneedle for rapid antidepressant therapy.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a global mental health crisis, and the rapid-acting antidepressant scopolamine (Scop) is limited by systemic administration drawbacks. This study developed a scopolamine-loaded bilayer dissolving microneedle (Scop-DMN) system for transdermal delivery and evaluated its antidepressant efficacy in a chronic restraint stress (CRS)-induced mouse model. Bilayer DMNs were fabricated via sequential centrifugal molding, with a polyvinyl alcohol (PVA) backing layer and a dextran‑sodium hyaluronate drug-loaded tip matrix. Physicochemical properties, biocompatibility, and in vivo therapeutic effects were systematically characterized. Scop-DMNs showed uniform conical morphology, high drug loading homogeneity, and complete dissolution within 2 min in porcine skin. In C57BL/6 J mice, Scop-DMNs significantly ameliorated CRS-induced depressive-like behaviors in open field, sucrose splash tests, and tail suspension tests 24 h post-administration, outperforming conventional intraperitoneal scopolamine. Mechanistically, Scop-DMNs robustly activated the brain-derived neurotrophic factor / mammalian target of rapamycin (BDNF/mTOR) pathway and upregulated synaptic proteins (postsynaptic density protein 95 (PSD95), Synapsin I (SynI)) in the medial prefrontal cortex (mPFC), reversing stress-induced neurotrophic and synaptic deficits. This Scop-DMN system provides a safe, minimally invasive, and effective transdermal platform for scopolamine delivery, offering a promising clinical strategy for rapid management of acute depressive episodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.